🇺🇸 FDA
Patent

US 8734799

Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer

granted A61KA61K2039/505A61P

Quick answer

US patent 8734799 (Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer) held by The Regents of the University of California expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61P, A61P35/00